According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
The settlement and dismissal resolves all claims between the parties
At present 18 per cent of the local pharmaceutical market is under government's price control
Innovative solutions and a deep understanding of the market makes this a unique combination
Subscribe To Our Newsletter & Stay Updated
